Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus TEXACORT.
HYDROCORTISONE SODIUM SUCCINATE vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid